Skip to content
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Loading stock detail

Preparing the latest stock view…

We're pulling the screening verdict, quote snapshot, and company context now.

Is Abbott India Ltd. Shariah Compliant? | BarakFi | BarakFi
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Home›Screener›ABBOTINDIA
ABBOTINDIA logo
ABBOTINDIANSE

Abbott India Ltd.

Healthcare · Large Cap · India
₹26,050
▼ ₹1,685 (-6.08%) today
Day Range: ₹26,005 – ₹26,420
Volume: 2.4K · as of 3 Jun 2026, 1:39 pm
Shariah Status
Requires Review
Report Credit
Opening this stock page uses 1 of your 50 monthly report credits.
Last screened 3 Jun 2026, 7:31 pm IST.
Methodology
AAOIFI aligned · 2026.04.2
See Full Breakdown
Requires Review
Compliance
Market Data
About
Similar Stocks
Add to Watchlist
Share
Shariah Compliance Breakdown
Debt Ratio
Interest-bearing debt compared to methodology denominator (AAOIFI: total assets). Must stay below 30%.
Disclaimer:The information on this page is for educational purposes only and does not constitute a religious ruling (fatwa) or financial advice. Shariah compliance status is derived from publicly available financial data and BarakFi's methodology mapping. Individual scholars may reach different conclusions. Always consult a qualified Islamic finance scholar and a licensed financial advisor before making investment decisions.
BarakFi

Shariah-compliant equity screening for the Indian market.

support@barakfi.inBarakFi on LinkedIn
Product
ScreenerWatchlistTrending
Resources
Halal Stocks IndiaAbout UsMethodologyPurificationSecurity
Legal
Terms of ServicePrivacy PolicyCookie PolicyDisclaimer
© 2026 BarakFi · Educational screening · Not a religious ruling or financial adviceMade in India
Threshold: 30%
Not disclosed
Borderline
Interest Income
Interest and treasury-based income as a share of business income. Must stay below 5%.
Threshold: 5%
0.0%
Pass
Non-permissible Income
Non-halal income compared to total business income. Must stay below 5%.
Threshold: 5%
Not detected
Pass
Accounts Receivable
Receivables compared to methodology denominator (AAOIFI: total assets). Must stay below 49%.
Threshold: 49%
6.4%
Pass
Business Activity
Core business lines should avoid prohibited sectors and interest-driven revenue dependence.
Allowed
Pass
Cash & Interest-bearing Assets
Cash, equivalents, and interest-bearing balances compared to total assets. Must stay below 30%.
Threshold: 30%
9.5%
Pass
Why Requires Review
Abbott India Ltd. currently screens as requires review on BarakFi. Insufficient data for: debt_ratio. Debt ratio: Total debt figure is missing from the latest reliable filing.
Market Data
Current Price
₹26,050
Day Range
₹26,005 – ₹26,420
52-Week Range
₹25,150 – ₹37,000
Volume
2.4K
Market Cap
₹55,864 Cr
P/E Ratio
—
About Abbott India Ltd.

Abbott India Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 3,700 full-time employees. The firm has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. The company provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. The company offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.

BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.

Index and universe context: Nifty 500 • Nifty SMALLCAP 100.

HealthcareLarge CapIndiaNSENifty 500Nifty SMALLCAP 100
Other Stocks in Healthcare
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Compliant
MAXHEALTH
Max Healthcare Institute Limited
Compliant
ZYDUSLIFE
Zydus Lifesciences Limited
Compliant
MANKIND
Mankind Pharma Limited
Compliant
FORTIS
Fortis Healthcare Limited
Compliant
Key Compliance Ratios
Debt RatioNot disclosed
Interest Income0.0%
Non-permissible IncomeNot detected
Receivables Ratio6.4%
Overall StatusRequires Review
Stock Information
TickerABBOTINDIA
ExchangeNSE
SectorHealthcare
CountryIndia
Market Cap₹55,864 Cr
36M Avg MCap₹58,861 Cr
Cap SizeLarge Cap
About this Screening
This page uses an AAOIFI-aligned methodology version 2026.04.2, checking debt, interest income, non-permissible income, receivables, and balance-sheet context from the current filings dataset.

This is educational only — not a religious ruling or financial advice. Read the full methodology for threshold context and update cadence.

Read full methodology →
Track this stock
Add ABBOTINDIA to your watchlist so you can revisit its status after the next fundamentals sync.
Open Watchlist